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Introduction: Preeclampsia (PE) carries increased risks of cardiovascular- and metabolic diseases in
mothers and offspring during the life course. While the severe early-onset PE (EOPE) phenotype origi-
nates from impaired placentation in early pregnancy, late-onset PE (LOPE) is in particular associated with
pre-existing maternal cardiovascular- and metabolic risk factors. We hypothesize that PE is associated
with altered epigenetic programming of placental and fetal tissues and that these epigenetic changes
might elucidate the increased cardiovascular- and metabolic disease susceptibility in PE offspring.
Methods: A nested case-control study was conducted in The Rotterdam Periconceptional Cohort
comprising 13 EOPE, 16 LOPE, and three control groups of 36 uncomplicated pregnancies, 27 normo-
tensive fetal growth restricted and 20 normotensive preterm birth (PTB) complicated pregnancies.
Placental tissue, newborn umbilical cord white blood cells (UC-WBC) and umbilical vein endothelial cells
were collected and DNA methylation of cytosine-guanine dinucleotides was measured by the Illumina
HumanMethylation450K BeadChip. An epigenome-wide analysis was performed by using multiple linear
regression models.
Results: Epigenome-wide tissue-speciﬁc analysis between EOPE and PTB controls revealed 5001 mostly
hypermethylated differentially methylated positions (DMPs) in UC-WBC and 869 mostly hypomethylated
DMPs in placental tissue, situated in or close to genes associated with cardiovascular-metabolic devel-
opmental pathways.
Discussion: This study shows differential methylation in UC-WBC and placental tissue in EOPE as
compared to PTB, identifying DMPs that are associated with cardiovascular system pathways. Future
studies should examine these loci and pathways in more detail to elucidate the associations between
prenatal PE exposure and the cardiovascular disease risk in offspring.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).t preeclampsia; LOPE, late-onset preeclampsia; UC-WBC, umbilical cord white blood cells; HUVEC, human umbilical vein
s; DMPs, differentially methylated positions; EWAS, epigenome-wide association studies; FGR, fetal growth restriction;
rval; GO-term, gene-ontology term; PBS, phosphate buffered saline-solution; MACS, magnetic activated cell separation;
pathway analysis; DAVID, Database for Annotation, Visualization and Integrated Discovery; PCA, Principal Component
Herzog), a.eggink@erasmusmc.nl (A.J. Eggink), s.willemsen@erasmusmc.nl (S.P. Willemsen), r.c.slieker@lumc.nl
nands), j.felix@erasmusmc.nl (J.F. Felix), chen.jun2@mayo.edu (J. Chen), a.stubbs@erasmusmc.nl (A. Stubbs), p.
eurs@erasmusmc.nl (J.B. van Meurs), r.steegers@erasmusmc.nl (R.P.M. Steegers-Theunissen).
Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Preeclampsia (PE) is a major cause of maternal and fetal
morbidity and mortality and is suggested to be associated with the
future risk of cardiovascular- and metabolic diseases in mothers
and offspring [1]. Two main disease entities have been identiﬁed.
Early-onset PE (EOPE) is the more severe phenotype originating
from impaired placentation during the ﬁrst trimester of pregnancy;
late-onset PE (LOPE) occurs in the third trimester mainly as a
consequence of exposure to pre-existing maternal cardiovascular-
and metabolic risk factors [2,3]. The exact pathophysiology of PE is
not understood, but it is known that in EOPE inadequate spiral
artery remodelling leads to ischaemia-reperfusion-type placental
insults [4]. This induces an excessive production of oxidative radi-
cals. As a result, pro-inﬂammatory cytokines are released into the
maternal circulation inducing endothelial dysfunction that leads to
the clinical symptoms of PE [4]. Excessive placental oxidative
stressors are also produced in LOPE but more towards the end of
pregnancy [2].
PE is considered a complex disease induced by gene- and
environmental interactions [5,6]. Altered epigenetic programming
of speciﬁc tissues, induced by excessive oxidative stress, has been
suggested to be an underlying mechanism [5]. Impaired placental
perfusion, excessive production of oxidative radicals, endothelial
dysfunction and immune modiﬁcations in PE may disturb epige-
netic programming in offspring tissues as well, resulting in de-
rangements of the vascular epigenome and function in the
offspring [7e10]. From this background we hypothesize that altered
epigenetic programming of especially placental tissues is associ-
ated with the pathogenesis of PE (as cause or consequence) and
with cardiovascular and metabolic risks in the offspring over the
life course [11].
Although PE has been associated with DNAmethylation changes
of candidate genes in placental and newborn tissue, only a few
epigenome-wide association studies (EWAS) have found new loci
of interest and most of these did not examine multiple tissues per
patient [12e17]. In this study we examined tissue-speciﬁc genome-
wide DNA methylation of umbilical cord white blood cells (UC-
WBC), placental tissue and human umbilical cord endothelial cells
(HUVEC) in relation to EOPE and LOPE.
Considering that PE is complicated by fetal growth restriction
(FGR) in 12% of cases and associated with iatrogenic preterm birth
(PTB) in 20%, which are conditions that can independently affect
epigenetic programming, we examined the epigenome of PE and
uncomplicated controls but also that of controls complicated by
FGR and PTB [18e20].
2. Materials and methods
2.1. Study design
Pregnant women and their newborn babies were recruited be-
tween June 2011 and June 2013 in a nested case-control study
embedded in The Rotterdam Periconceptional Cohort (Predict
study), at the Erasmus MC, University Medical Centre Rotterdam,
the Netherlands [21]. Cases comprised of EOPE and LOPE, and un-
matched controls comprised of uncomplicated pregnancies and
FGR and PTB complicated pregnancies. Patients were recruited for
our case-control study by two different pathways. The ﬁrst
pathway contains subjects that were included in the Predict study
in the ﬁrst trimester and developed PE later in pregnancy. The
second pathway contains subjects that were admitted to our hos-
pital because of PE after the ﬁrst trimester, and were speciﬁcally
recruited in the Predict Study for our case-control study. This also
applies to our (un)complicated control groups.2.2. Maternal and fetal characteristics
PE was deﬁned according to the International Society for the
Study of Hypertension in Pregnancy as gestational hypertension of
at least 140/90 mmHg accompanied by a urine protein/creatinine
ratio of 30 mg/mmol arising de novo after the 20th week of
gestation [22]. EOPE and LOPE were deﬁned as being diagnosed
before and after 34 weeks of gestation, respectively [23]. Uncom-
plicated pregnancies were deﬁned as pregnancies without the
following pregnancy-speciﬁc complications: PE, gestational hy-
pertension, FGR or PTB. FGR was deﬁned as an estimated fetal
weight below the 10th percentile for gestational age based on ul-
trasound measurements performed between 20 and 38 weeks
gestational age [24]. Birth weight percentiles were calculated using
the reference curves of the Dutch Perinatal Registry to validate
birth weight <10th percentile [25]. Spontaneous preterm deliveries
between 22 and 37 weeks of gestation were deﬁned as PTB [26].
Women with HIV infection, aged <18 years, not able to read and
understand the Dutch language, multiple birth pregnancies or
women with pregnancies complicated by fetal congenital malfor-
mations were excluded.
Maternal and newborn characteristics were obtained from
hospital medical records. All women gave written informed con-
sent before participation and parental informed consent was ob-
tained for the child. The research has been carried out in
accordance with the Declaration of Helsinki (2013) of the World
Medical Association.
2.3. Data collection
UC-WBC samples from the umbilical vein were collected with
the placenta still in situ. Thereafter, placental tissue was obtained
and HUVEC were isolated and stored until DNA extraction. A
detailed description of the data collection, UC-WBC processing,
HUVEC isolation and DNA extraction is provided in Appendix 1.
2.4. DNA methylation measurement
Isolated genomic DNA (500 ng) was treated with sodium
bisulphite using the EZ-96 DNA methylation kit (Shallow) (Zymo
Research, Irvine, CA, USA). Hybridization was performed following
manufacturer's instructions. DNA methylation of CpGs was
measured by the Illumina HumanMethylation450K BeadChip using
the manufacturer's protocol (Illumina, Inc., San Diego, CA, USA)
[27e29]. Data quality control and pre-processing is described in
Appendix 2.
2.5. Differentially methylated position (DMP) identiﬁcation
To improve statistical power, prior to further statistical analysis
a selection of probes containing at least 0.05 SD variability in
methylation b-values across all samples was applied for each tissue
separately [30]. This resulted in a remaining total of 43,488 UC-
WBC probes, 134,700 placental probes and 42,352 HUVEC probes.
Methylation b-values were converted to M-values using: M-
value¼ log2 (b-value/(1-b-value)) [31]. A multiple linear regression
model was used predicting methylation M-values by disease state
for EOPE and LOPE versus (un)complicated controls, adjusted for
bisulphite-plate batch and gestational age as covariates for each
tissue separately (R package ‘CpGassoc’). Sensitivity analyses were
performed for the following covariates: batch-effect of the
bisulphite-plate, gestational age, birth weight, fetal gender,
maternal comorbidity, mode of delivery and moment of inclusion
for the study in or >1st trimester. Only gestational age and
bisulphite-platewere thereafter included in our statistical model as
E.M. Herzog et al. / Placenta 58 (2017) 122e132124potential confounders.
UC-WBC analyses were performed with additional adjustment
for total number of UC-WBC leucocytes (x109/L), available from our
ﬂow-cytometric data (n ¼ 61, 70%) or otherwise imputed (n ¼ 27,
30%) [32]. Missing leucocyte numbers were imputed by ‘Multiple
Imputations with Chained Equations’ using other available UC-WBC
variables and all contributing maternal and fetal characteristics
with maternal age2 as the best predictive variable (package mice)
[33]. Additionally, Houseman-data was applied during imputation,
further predicting proportions of lymphocytes, monocytes and
granulocytes based on a community cohort of 94 non-diseased,
non-smoking, predominantly female individuals between 24 and
45 years old, which improved the Akaike Information Criterion by
11 [34]. Imputed leucocyte concentrations are given in
Supplementary Table 1. Due to sample size constraints we could not
adjust for further differentiated white blood cell counts.
We used the following model:
Mi ¼ b0 þ b1G þ b2GA þ b3PLATE2 þ b4PLATE3 þ (þb5UC-WBC-
leucocytes) þ εi.
where Mi is the (base 2) logit of the methylation of individual i. G is
the group indicator variable (that is one if the sample corresponds
to EOPE or LOPE and zero otherwise), GA is gestational age and
PLATE2 and PLATE3 are indicator variables for the sample plates. b5
is only applied for the UC-WBC analysis. εi is the residual error
assumed to derive from a normal distribution.
A False Discovery Rate (FDR) adjusted p-value below 0.05 was
considered signiﬁcant. CpG sites were classiﬁed as DMP if statisti-
cally signiﬁcant and presenting with a minimal effect-size DM of
0.8. We considered various M-value cut-off values for further data
analysis and applied the widely used robust cut-off of 12.5% DbFig. 1. Overview of the study population and sample distribution.
Legend: EOPE, early-onset preeclampsia; LOPE, late-onset preeclampsia; FGR, fetal growth re
umbilical vein endothelial cells; no., number of.(~0.8 on M-value scale) (Supplementary Table 2, Supplementary
Fig. 2) [13,35]. For the comparison with the smallest number of
samples (n ¼ 8 HUVEC samples in EOPE), we were able to measure
methylation differences of at least 10% Db or higher, with a power of
0.7 (sd of 0.05 and FDR<0.05). An arbitrary selection of 100
epigenome-wide signiﬁcant hits was subjected to a critical
assessment of M-value plots to exclude potential outlier-driven hits
or residual single nucleotide polymorphism-interference.
A detailed description of the DMP CpG-density- and gene-
centric enrichment analysis, Gene Ontology (GO) term enrich-
ment analysis and Ingenuity Pathway Analysis (IPA) is provided in
Appendix 3.
3. Results
All eligible pregnancies that met the inclusion criteria and
provided sufﬁcient tissues were included for the case-control
analysis. After exclusion of 2 misclassiﬁed pregnancies the ﬁnal
study population consisted of 112 pregnancies. The 29 PE preg-
nancies comprised of 13 EOPE and 16 LOPE pregnancies, and con-
trols included 36 uncomplicated and 27 FGR- and 20 PTB
complicated control pregnancies (Fig. 1). The number of patients is
a result of the initially aimed number of 25 samples per tissue per
case-control group. Because we were unable to collect this exact
amount of samples and because we obtained often more samples
from one patient, the number of corresponding patients differs for
each case-control group.
Maternal and newborn characteristics are shown in Table 1. In
addition to signiﬁcantly different PE-speciﬁc parameters, such as
blood pressure, proteinuria, gestational age and birth weight, nul-
liparity was more frequent in EOPE (84.6%) and LOPE (81.3%) than
in uncomplicated controls (30.6%, overall p ¼ 0.001). Caesareanstriction; PTB, preterm birth; UC-WBC, umbilical cord white blood cells; HUVEC, human
Table 1
Maternal and newborn characteristics.





(n ¼ 13) (n ¼ 16) (n ¼ 36) (n ¼ 27) (n ¼ 20) p-value
Age (years) 30.0 (4.7) 33.3 (4.5) 31.8 (5.1) 29.7 (6.0) 31.0 (5.1) 0.187
Nulliparous, n (%) 11 (84.6) 13 (81.3) 11*# (30.6) 17 (63.0) 10 (50.0) 0.001
Caesarean section, n (%) 11 (84.6) 5* (31.3) 10* (27.8) 9* (33.3) 4* (20.0) 0.002
Ethnicity, n (%)
Western geographic origin 12 (92.3) 9 (56.3) 30 (83.4) 17 (63.0) 18 (90.0) 0.074
Non-Western geographic origin 1 (7.7) 7 (43.8) 6 (16.7) 10 (37.0) 2 (10.0)
Preconception BMIa (kg/m2) 24.7 (10.1) 24.1 (4.4) 23.7 (4.8) 23.0 (6.5) 23.8 (6.1) 0.668
Smoking during pregnancy (yes), n (%) 2 (18.2) 0 (0.0) 0 (0.0) 2 (8.0) 2 (10.5) 0.132
Comorbidity (yes), n (%) 1 (7.7) 7 (43.8) 8 (22.2) 7 (25.9) 4 (20.0) 0.260
Newborn characteristics
Male gender, n (%) 3 (23.1) 7 (43.8) 21 (58.3) 15 (55.6) 10 (50.0) 0.253
Gestational age at birtha (weeks) 30.7 (3.4) 37.4* (1.9) 39.9*# (1.9) 38.9* (2.6) 35.4*# (7.9) <0.001
Birth weighta (grams) 1185 (481) 3183* (1244) 3713*# (551) 2630*# (595) 2660*# (1805) <0.001
Birth weight <10th percentile, n (%) 1 (7.7) 3 (18.8) 0# (0.0) 27*# (100.0) 0 (0.0) <0.001
Data are presented as mean (standard deviation) with corresponding ANOVA testing to examine overall differences between the groups, followed by the post hoc Dunnett t-
test for pairwise comparisons of EOPE and LOPE with (un)complicated controls.
Data are presented as number (%) with corresponding Chi2/Fischer's exact testing.
*p < 0.05 versus EOPE pregnancies. #p < 0.05 versus LOPE pregnancies.
ANOVA, analysis of variance; BMI, body mass index; EOPE, early-onset preeclampsia; LOPE, late-onset preeclampsia; FGR, fetal growth restriction; PTB, preterm birth.
a Non-parametric data are presented as median (interquartile range) with corresponding Kruskall-Wallis testing and posthoc Mann-Whitney testing.
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(31.3%) and (un)complicated controls (20.0e33.3%, overall
p ¼ 0.002). In the EOPE group, one pregnancy was complicated by
FGR (7.7%) and all by PTB; in the LOPE group, three pregnancies
(18.8%) were complicated by FGR (p ¼ 0.606, in comparison to the
EOPE group) and three (18.8%) by PTB (p < 0.001, in comparison to
the EOPE group).
3.1. DMP identiﬁcation
Genome-wide DNA methylation data revealed an overall
bimodal distribution for UC-WBC and HUVEC (Fig. 2). In these tis-
sues, only a small amount of cytosine-guanine dinucleotides (CpGs)
demonstrated methylation levels around 50%. In placental tissue
however, more CpGs presented 50% methylation levels. Methyl-
ation levels in placental tissue and HUVEC were comparable in allFig. 2. Density plot of b-values per tissue and per group.
Legend: Density plots show the b-value-densities for UC-WBC (A), placenta (B) and HUVEC
methylation levels. In addition, the placenta demonstrated a larger amount of CpGs with me
from LOPE and (un)complicated control pregnancies.
EOPE, early-onset preeclampsia; LOPE, late-onset preeclampsia; FGR, fetal growth restriction;
vein endothelial cells; CpGs, cytosine-guanine dinucleotides.groups, but in EOPE the methylation levels in UC-WBC clearly
deviated from those in all other groups.
A heatmap based on the clustering of methylation according to
CpG and sample depicts prominent clustering of the three different
tissues (Fig. 3A). We therefore also examined clustering per tissue,
which demonstrated EOPE clustering in UC-WBC but no clustering
in the placental- and HUVEC samples (Fig. 3BeD). This was vali-
dated by a principal component analysis (PCA) (Supplementary
Fig. 1).
Differences between EOPE, LOPE and (un)complicated controls
were examined in an epigenome-wide analysis. In the comparison
of EOPE and PTB we found 12,040 (28%) differentially methylated
CpGs in UC-WBC and 5,668 (0.5%) differentially methylated CpGs in
placenta. One differentially methylated CpG each was found in the
comparison of EOPE and uncomplicated controls in placental tissue
and in HUVEC, and in the comparison of EOPE and FGR in placental(C). Genome-wide DNA methylation data revealed an overall bimodal distribution of
thylation levels around 50%, in contrast to the other tissues. In UC-WBC, EOPE deviates
PTB, preterm birth; UC-WBC, umbilical cord white blood cells; HUVEC, human umbilical
Fig. 3. Heatmap based on clustering of methylation (b-value) of all differentially methylated CpGs.
Legend: Heatmap plots show the clustering results of the EWAS using all signiﬁcant CpGs in all tissues (A), UC-WBC samples (B), placental samples (C) and HUVEC samples (D).
Samples are plotted on the horizontal axis and CpGs on the vertical axis. Samples cluster between the different tissues (A) and between EOPE and the (un)complicated control
groups in UC-WBC samples (B). b-values are depicted for a better biological understanding of the ﬁgure.
EOPE, early-onset preeclampsia; LOPE, late-onset preeclampsia; FGR, fetal growth restriction; PTB, preterm birth; UC-WBC, umbilical cord white blood cells; HUVEC, human umbilical
vein endothelial cells.
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CpGs were found in the comparisons of LOPE and (un)complicated
controls. Differentially methylated CpGs with an effect size >0.8 in
M-value (logit2 of the b-value), representing an approximate
change in b-value of 12.5%, were deﬁned as differentially methyl-
ated positions (DMPs), which left 5,001 DMPs in UC-WBC and 869
DMPs in placenta in EOPE compared to PTB (Supplementary
Table 2). 25 DMPs are overlapping between UC-WBC and
placenta, which corresponds to 152 shared genes between UC-WBC
and placenta. In UC-WBC, 71% of DMPs were hypermethylated; in
contrast, hypomethylation was seen in 67% of the placental DMPs.
Of the shared set of DMPs, 13 (52%) share the same methylation
direction in both tissues and 54 (36%) genes are overlapping inmethylation direction (Fig. 4). All (overlapping) UC-WBC and
placental DMP identiﬁers are listed in Supplementary Table 3.
3.2. CpG-density- and gene-centric enrichment of DMPs
To evaluate whether DMPs were enriched in certain genomic
annotations, CpG island- and gene-centric annotations of UC-WBC-
and placental DMPs were examined (Fig. 5 and Supplementary
Table 4). DMP enrichment analysis relative to CpG islands
revealed exactly opposite patterns for UC-WBC and placental DMPs
with the strongest enrichment in non-CpG island regions and
strongest depletion in CpG islands in UC-WBC (ORUCWBC 1.61, 95%
CI 1.52e1.71 and ORUCWBC 0.23, 95% CI 0.20e0.26, respectively)
Fig. 4. Venn diagram of the number of (overlapping) UC-WBC- and placental DMPs in EOPE compared with PTB complicated pregnancies.
Legend: Red circles display the number of hypermethylated DMPs relative to PTB (þ), green circles display the number of hypomethylated DMPs relative to PTB (). UC-WBC,
umbilical cord white blood cells; DMPs, differentially methylated positions; EOPE, early-onset preeclampsia; PTB, preterm birth; no., number of.
Fig. 5. UC-WBC- and placental- DMP enrichment in the CpG-density (A) and gene-centric (B) annotation, in EOPE compared to PTB complicated pregnancies.
Legend: A. DMP annotation relative to CpG islands showed exactly opposite patterns for UC-WBC as compared to placental DMPs with the strongest enrichment in non-CpG island
regions and strongest depletion in CpG islands in UC-WBC versus strongest enrichment in CpG island regions and strongest depletion in non-CpG islands in placenta.
B. DMP annotation relative to genes, revealed strongest enrichment in gene body regions, with additional high enrichment in downstream regions of the placenta. A strong
depletion of DMPs in intergenic regions was observed in both UC-WBC and placental tissue.
*p < 0.05. UC-WBC, umbilical cord white blood cells; EOPE, early-onset preeclampsia; PTB, preterm birth; non-CGI, non-CpG island; DMP, differentially methylated position.
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depletion in non-CpG islands in placenta (ORPlacenta 1.33, 95% CI
1.15e1.54 and ORPlacenta 0.72, 95% CI 0.62e0.83, respectively) (Fig. 5
and Supplementary Table 4).
The location of DMPs relative to genes revealed the strongest
enrichment in gene bodies with additional high enrichment in
downstream regions of the placenta. A strong depletion of DMPs in
intergenic regions was observed in both UC-WBC and placental
tissue (ORUCWBC 0.53, 95% CI 0.49e0.58, ORPlacenta 0.63, 95% CI
0.53e0.75).3.3. Gene-ontology (GO) term enrichment of DMP genes
To gain more insight in functionality, the DMPs were mapped to
the nearest gene. This yielded 3,444 unique UC-WBC genes and 697
unique placental genes. The 3,444 UC-WBC DMP genes mapped to
2,744 genes in The Database for Annotation, Visualization and In-
tegrated Discovery (DAVID) after discarding the remaining DMP
annotations as transcripts. These genes were enriched for
involvement in cell signalling processes and regulation of cell
death, gene expression, RAS-activity, inﬂammatory responses and
erythrocyte development. After excluding those DMPs that were
mapped to transcripts instead of genes, DAVID mapped 536
E.M. Herzog et al. / Placenta 58 (2017) 122e132128placental DMP genes and revealed enriched GO term involvement
in embryogenesis, regulation of transcription and cellular differ-
entiation. UC-WBC and placental highest enriched GO terms are
presented in Table 2.
3.4. Ingenuity pathway analysis (IPA) of DMP genes
We applied IPA to validate the GO ﬁndings from DAVID. In-
genuity software mapped 3,011 UC-WBC DMP genes and a canon-
ical pathway analysis identiﬁed enrichment of top-ranked
pathways all involved in cascade-signalling mechanisms. We
further conducted network analyses, which revealed that the top
networks were mainly associated with cardiovascular system
development, cellular function and development, haematological
system development and infectious diseases.
596 placental DMP genes were mapped by Ingenuity, of which
enriched canonical pathways did not reach statistical signiﬁcance.
The top ten enriched networks were mainly associated with em-
bryonic development, cellular development, regulation of gene
expression, cardiovascular system development, cell death and
survival and haematological system development. The highest
enriched pathways and networks are presented in Table 3.
4. Discussion
In this study we demonstrate signiﬁcant differences in genome-Table 2





2. Programming of cell death 3.9
3. Cytoskeleton organization 3.9
4. Positive regulation of gene expression 3.6
5. Regulation of RAS (GTPase) activity 3.3
6. Endocytose 2.8
7. Regulation of phosphate metabolic process 2.7
8. Defence/inﬂammatory response 2.4
9. Erythrocyte differentiation and development 2.1
10. Regulation of endocytosis and phagocytosis 2.0
Placenta Enrichment
score
1. Embryonic development 7.3
2. Regulation of transcription 7.2
3. Neuron development 6.3
4. Embryonic morphogenesis 5.7
5. Positive regulation of transcription 4.9
6. Negative regulation of transcription 4.2
7. Embryonic morphogenesis 4.1
8. Respiratory development 3.9
9. Regulation of cell differentiation and development 3.5
10. Embryonic development: dorsal/ventral pattern
formation
3.4
UC-WBC- and placental DMPs in EOPE were mapped to the nearest gene using
Ensembl annotations from UCSC database. Assigned Ensembl genes were uploaded
to the DAVID tool to examine possible enrichment of corresponding GO terms using
the GO_BP_FAT annotation category. Fisher Exact was applied to measure the gene-
enrichment of annotated GO terms of the uploaded gene list, against the whole
human genome list as a background. To focus on the biology of the annotated GO
terms, clusters of similar annotations were examined from the DAVID Functional
annotation Clustering table tool. The clustering algorithm is based on the hypothesis
that similar annotations have similar gene members, resulting in a Group Enrich-
ment Score to rank their biological signiﬁcance, which is based on the Fisher Exact
p-values of each GO term within the cluster. The higher the enrichment score, the
more enriched.
DMPs, differentially methylated positions; DAVID, Database for Annotation, Visual-
ization and Integrated Discovery; GO-term, gene-ontology term; HUVEC, human
umbilical vein endothelial cells.wide UC-WBC and placental DNA methylation between EOPE and
PTB controls but not between EOPE and FGR controls or uncom-
plicated controls. Signiﬁcant differences were also not found be-
tween LOPE and all other (un)complicated control pregnancies.
4.1. EOPE differential methylation in comparison to PTB, in UC-WBC
and placental tissue
Our most evident observation was the large difference in the
level of differential methylation observed in EOPE but not in LOPE.
This may be best explained by the excessive oxidative stress
exposure in EOPE and LOPE pregnancies, suggested to be highly
involved in the disturbance of epigenetic programming [7]. In
response to various forms of stress, cells increase the production of
important protective proteins while reducing the translation of
other less relevant proteins to restore cellular homeostasis [36]. We
observed both hyper- and hypomethylation in association with
EOPE in UC-WBC and placenta tissue, and enrichment of both
positive and negative regulation of transcription among the func-
tional annotations of DMP genes, in line with these cellular stress
responses. Moreover, if cellular stress responses fail or a sudden
excessive stress event occurs, cellular death might occur, through
apoptosis or necrosis [37]. Also this cellular death- and survival
pathway was identiﬁed among the DMP gene functional annota-
tions, underlining the potential involvement of excessive oxidative
stress.
From our data it appears that oxidative stress may have more
consequences for EOPE pregnancies, where placental and newborn
tissues are indeed subjected to this adverse exposure from early
pregnancy onwards. In EOPE, chorionic villi are exposed to oxida-
tive stress at 8e9weeks of gestation through contact withmaternal
oxygenated blood due to early unplugging of spiral arteries, dis-
turbing the formation of the deﬁnitive placenta by restricted in-
vasion and impaired remodelling of spiral arteries [36]. One might
hypothesize that the epigenetic programming involved in this
initial placental formation and differentiation is in fact already
affected, perhaps inducing the further development of EOPE, rather
than being a consequence of the disease. We suggest that perhaps
the very initial process of epigenetic reprogramming between fer-
tilisation and formation of the blastocyst is already affected in
EOPE, explaining the observed extensive involvement of placental
DMPs and also suggesting a more causative epigenetic involve-
ment. In general, impaired placentation seems to play a much
larger role in the pathophysiology of EOPE than LOPE, with more
adverse consequences for the fetus, such as FGR, supporting the
current results [2]. Also the maternal and fetal pro-inﬂammatory
milieu is more pronounced in EOPE than in LOPE, with more po-
tential consequences for UC-WBC epigenetic programming, as
substantiated by our data [7].
Although we would have expected to establish some degree of
differential methylation in LOPE, the lack of differential methyl-
ation is in accordance to previous literature [12,13,38e40]. Only
Zhu et al. identiﬁed DMRs in placental tissue of severe LOPE
pregnancies as compared to that of gestational age- and parity-
matched controls. They however used different techniques (DNA
immunoprecipitation and deep sequencing) and included only se-
vere cases of LOPE, potentially explaining the discrepancy with our
ﬁndings [16].
A possible reason for observing associations between EOPE and
PTB only, is that these two groups are least affected by a larger
gestational age range and additional comorbidity and hence easier
to compare than the other control groups. The lack of any signiﬁ-
cantly differential methylation in HUVEC obtained from EOPE
pregnancies might be partly explained by the decreased power as a
result of the lower HUVEC sample size (n ¼ 8) and the larger
Table 3
Top 10 Ingenuity networks and pathways of EOPE UC-WBC- and placental DMP nearest genes.
UC-WBC Canonical pathways -log p-value
1. Molecular Mechanisms of Cancer 4,49
2. Tec Kinase Signalling 4,37
3. Relaxin Signalling 4,37
4. IL-1 Signalling 4,00
5. Fcg Receptor-mediated Phagocytosis in Macrophages and Monocytes 3,87
6. PPAR Signalling 3,78
7. Renal Cell Carcinoma Signalling 3,74
8. G Beta Gamma Signalling 3,67
9. G-Protein Coupled Receptor Signalling 3,67
10. HGF Signalling 3,49
UC-WBC networks Score
1. Cardiovascular System Development and Function, Lymphoid Tissue Structure and Development, Cell Morphology 29/35
2. Cardiovascular System Development and Function, Tissue Morphology, Cellular Movement 26/34
3. Cell Cycle, Cellular Development, Haematological System Development and Function 24/33
4. Connective Tissue Disorders, Developmental Disorder, Skeletal and Muscular Disorders 24/33
5. Cancer, Organismal Injury and Abnormalities, RNA Post-Transcriptional Modiﬁcation 24/33
6. Cardiovascular Disease, Cellular Compromise, Organismal Injury and Abnormalities 23/32
7. Infectious Diseases, Antigen Presentation, Protein Synthesis 23/32
8. RNA Damage and Repair, Post-Translational Modiﬁcation, Cellular Development 23/32
9. Cell Morphology, Cellular Function and Maintenance, Infectious Diseases 23/32
10. Cancer, Organismal Injury and Abnormalities, Reproductive System Disease 23/32
placental networks Score
1. Embryonic Development, Hereditary Disorder, Neurological Disease 45/32
2. Cellular Development, Cellular Growth and Proliferation, Organismal Development 36/28
3. Gene Expression, Cancer, Organismal Injury and Abnormalities 36/28
4. Cell Cycle, Cellular Movement, Developmental Disorder 30/25
5. Cardiovascular System Development and Function, Cellular Movement, Carbohydrate Metabolism 25/22
6. Molecular Transport, Inﬂammatory Response, Haematological System Development and Function 14/15
7. Metabolic Disease, Organismal Injury and Abnormalities, Respiratory Disease 12/14
8. Cellular Development, Cellular Growth and Proliferation, Cellular Movement 12/14
9. Cell Death and Survival, Cell Cycle, Cellular Assembly and Organization 12/14
10. Cell Death and Survival, Cardiovascular System Development and Function, Cell Morphology 12/14
Ingenuity pathway analysis was performed with the annotated UC-WBC- and placental DMP Ensembl gene lists in EOPE with focus on canonical pathways and
networks. Enriched canonical pathways were calculated using the Fisher's Exact test and subjected to Benjamini-Hochberg procedure for controlling FDR (p < 0.05).
Networks were generated based on network eligible molecules, which were encoded by our DMP genes and also interact with other molecules in the Ingenuity
Pathways Knowledge Base. A high score for a network indicates a more approximate ﬁt between network eligible molecules and the molecules that constitute the
network, calculated using the right-tailed Fisher's Exact Test. No signiﬁcant EOPE placental canonical pathways were observed.
DMPs, differentially methylated positions; HUVEC, human umbilical vein endothelial cells; FDR, false discovery rate.
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The majority of DMPs in placental tissue was hypomethylated,
which is substantiated by literature [13,38e41], whereas the more
prominent hypermethylation in UC-WBC is in contrast to previous
studies [14,42]. These studies did not adjust for potential con-
founders such as gestational age or leucocyte-count, which may
explain the discrepancy of the results. Compared to the total
number of DMPs, the relatively small shared set of 25 DMPs and 152
corresponding genes suggests that UC-WBC and placenta are
behaving rather differently in association to EOPE. This is sub-
stantiated by the fact that only 52% of the shared DMPs and 36% of
the shared genes in UC-WBC and placental tissue are behaving in
the same methylation direction relative to PTB, and by the opposite
enrichment patterns described below. In certain overlapping genes
it appears that different CpGs are affected in UC-WBC than in
placental tissue.
4.2. CpG-density- and gene-centric enrichment of EOPE UC-WBC-
and placental DMPs
Enrichment analysis of the identiﬁed EOPE DMPs showed
opposite patterns for the positions of UC-WBC- and placental DMPs
relative to CpG-islands. EOPE was associated with strong differen-
tial methylation of non-CpG island regions in UC-WBC and deple-
tion in CpG islands, whereas in placental tissue differential
methylationwas observed in CpG islands and depletion in non-CpG
islands, which is in line with previous studies [13,14]. Evidenceemerges that CpG island methylation is mostly associated with
long-term repression of gene expression such as imprinting, which
is an important process for normal placental development [11,43].
Indeed, a supporting role of imprinting in the development of PE
has been observed in previous studies [44].
UC-WBC- and placental DMPs display strong enrichment in
gene bodies and evident depletion in intergenic regions. Previous
studies describe enrichment of EOPE DMPs in placental enhancer-
and UC-WBC ‘open sea’-regions, classiﬁed according to the Illumina
gene-centric annotation which is not directly comparable to our
UCSC gene-centric annotation results. Gene body regions seem to
be more susceptible to variation in DNA methylation, and may
therefore represent interesting genomic regions for future epide-
miologic epigenetic association studies [43]. Because methylation
of gene bodies is generally associated with stimulation of tran-
scription, the strong placental hypomethylation suggests mainly
repression of transcription and the contrary for UC-WBC [43].
4.3. GO-term enrichment and IPA of EOPE DMP genes
DMP GO functional annotations demonstrated that genes linked
to UC-WBC DMPs were involved in many processes associated with
the pathogenesis of PE, such as regulation of inﬂammatory re-
sponses and RAS-activity [3,45]. We and others have previously
described decreased leucocytes and increased nucleated red blood
cells in EOPE UC-WBC, indeed suggesting inﬂammatory response
involvement and disturbed fetal haematopoiesis [46,47]. Therefore,
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development. The observed enriched GO-term of cellular death
regulationmight be related to ﬂawing of the endothelial vessel wall
in PE, causing apoptosis of endothelial cells, which has been related
to the increased presence of endothelial microparticles in PE [7].
One of the most enriched UC-WBC GO terms covers a broad spec-
trum of cell signalling processes involved in many general pro-
cesses, which is likely a result of general excessive oxidative
stressors. The latter was conﬁrmed by all highest signiﬁcant ca-
nonical pathways from IPA. Placental DMP GO functions covered
general functions such as cellular differentiation and cell death,
embryogenesis and regulation of gene expression, which is in
agreement to the impaired placentation and compromised fetal
growth in EOPE and substantiated by literature [13].
The involvement of DNA methylation differences in cardiovas-
cular programming of PE offspring was strongly suggested bymany
identiﬁed gene-ontology (GO) functional annotations and path-
ways associated with the DMP genes. Repeated enrichment of IPA
genetic networks associated with development of cardiovascular
and metabolic disease was observed. This is partly substantiated by
previous PE EWAS, describing differential methylation in the fatty
acid synthase pathway and in collagen-related genes [12,14]. There
exists partial overlap between identiﬁed genes in association with
EOPE in previous EWAS in both UC-WBC and placental DMP-genes,
as depicted in Supplementary Table 3. We believe these over-
lapping genes might represent interesting loci for further research
and suggest a certain degree of reproducibility of our results. Yuen
et al. identiﬁed hypomethylation of the TIMP3 gene in EOPE pla-
centas, suggesting reduced angiogenesis and trophoblast inva-
siveness by use of the Illumina GoldenGate Methylation assay [40].
In other vascular-related candidate gene studies, altered DNA
methylation in association with PE was found of LEP, VEGF, FLT-1,
KDR-genes and collagen-metabolism genes [39,41,48], substanti-
ating the role of disturbed vascular programming in PE. All of these
previously identiﬁed candidate genes were also present among our
DMPs in UC-WBC and/or placental tissue.
Several studies have demonstrated that epigenetic program-
ming may indeed be involved in the development of cardiovascular
disease, as reviewed by Casanello et al. [49]. One of these studies
showed increased DNA methylation of estrogen receptor beta
promotors in endothelial cells of atherosclerotic plaques [50].
Alexander at al. showed that in smooth muscle cells epigenetic
mechanisms were involved in the phenotypic switch to less
contractility with vascular dysfunction as a result [51].
4.4. Strengths and limitations
The design of our EWAS is unique in that it addresses tissue-
speciﬁc methylation levels of EOPE and LOPE and uses both un-
complicated and FGR- and PTB-complicated normotensive control
pregnancies. The different tissues were obtained mostly from the
same pregnancies and therefore the data provide novel insights in
the tissue-speciﬁc epigenome-wide DNA-methylation in PE-
exposed newborn tissues. Moreover, we adjusted for gestational
age and UC-WBC cell mixtures [20,40], which has not often been
done in previous studies [12,14,15]. The UC-WBC cell populations
were however partly estimated, based on our own and external
populations. Our description of the standardised tissue sampling is
more extensive than in most other studies, and this is relevant
because the method of tissue sampling can be an important po-
tential confounder or effect modiﬁer of DNA methylation [52,53].
Inherent to the observational and case-control character of the
study, residual confounding cannot be fully excluded. The addition
of birthweight as potential confounder did not improve our sta-
tistical model and was discarded also because of the limited samplesize. Moreover, we had no expression data to validate our ﬁndings
and the external validity is reduced by the relatively high presence
of comorbidities in uncomplicated controls in our tertiary hospital
setting. Our ﬁndings could have improved with the use of larger
sample sizes and homogeneous cell types of placental tissue and
UC-WBC, thereby avoiding potential confounding by cell mixture
variation, [54,55].4.5. Conclusion
We found a large number of genome-wide DMPs in UC-WBC
and placental tissue that were associated with EOPE. The enrich-
ment in several cardiovascular system developmental pathways
implies that epigenetic programming may be an underlying
mechanism explaining the association with increased cardiovas-
cular disease risks in EOPE offspring. Future follow-up studies in
offspring should address whether these pathways represent po-
tential targets for intervention or prevention of the enhanced car-
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